SG/CALL/NOVO-NORDISK B/1100/0.1/20.12.24 | Market Closed - Boerse Frankfurt Warrants 20:36:12 21/06/2024 BST | ||
| 0.83 EUR | +3.75% |
|
| Current month | +45.61% | ||
| 1 month | +31.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 21/06/24 | 0.83 | +3.75% |
| 20/06/24 | 0.8 | +3.90% |
| 19/06/24 | 0.77 | -2.53% |
| 18/06/24 | 0.79 | -3.66% |
| 17/06/24 | 0.82 | -6.82% |
Real-time Boerse Frankfurt Warrants
Last update June 21, 2024 at 08:36 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SU9GMB |
| ISIN | DE000SU9GMB4 |
| Date issued | 16/02/2024 |
| Strike | 1,100 kr |
| Maturity | 20/12/2024 (180 Days) |
| Parity | 10 : 1 |
| Emission price | 0.53 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.98 € |
|---|---|
| Lowest since issue | 0.41 € |
| Spread | 0.02 € |
| Spread % | 2.35% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
987.9
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.43%
- Stock Market
- Warrants
- Warrant
